Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system

被引:2
|
作者
Liang, Yankun [1 ,2 ]
Ma, Lin [3 ]
Wang, Yuting [2 ]
Zheng, Jingping [2 ]
Su, Ling [2 ]
Lyu, Jun [1 ,4 ]
机构
[1] Jinan Univ, Affiliated Hosp 1, Dept Clin Res, Guangzhou, Guangdong, Peoples R China
[2] Jinan Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Prov Hosp Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Prov Key Lab Tradit Chinese Med Informat, Guangzhou, Guangdong, Peoples R China
关键词
molnupiravir; pharmacovigilance; coronavirus disease 2019; food and drug administration adverse event reporting system; adverse events; safety; COVID-19;
D O I
10.3389/fphar.2023.1253799
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Molnupiravir, an urgently approved drug during the Coronavirus Disease 2019 (COVID-19) pandemic, serves as the basis for our study, which relies on the Food and Drug Administration Adverse Event Reporting System (FAERS). The objective is to extract adverse event (AE) signals associated with molnupiravir from the FAERS database, thereby providing a reference for post-marketing monitoring of adverse events. Specifically, we extracted individual case safety reports (ICSRs) from the database, focusing on cases with COVID-19 indications and molnupiravir identified as the primary suspect drug. Descriptive analysis of the extracted data was performed, followed by four disproportionality analyses using the reporting odds ratio (ROR) method. These analyses were conducted across four levels, encompassing overall data, reports by health professionals, as well as age and gender differentiations, ensuring the robustness of the analysis results. In total, 116,576 ICSRs with COVID-19 indications and 2,285 ICSRs with molnupiravir as the primary suspect were extracted. Notably, after excluding cases with unknown age or gender, a higher proportion of molnupiravir-related ICSRs were observed among individuals aged 65 years and older (70.07%) and women (54.06%). The most frequently reported adverse events and AE signals were associated with gastrointestinal disorders, as well as skin and subcutaneous tissue disorders. Moreover, individuals aged 65 years and older exhibited a higher risk of cardiac disorders, hepatobiliary disorders, renal and urinary disorders, and vascular disorders. In conclusion, this study found molnupiravir demonstrated a lower risk of serious adverse events compared to other RNA antiviral drugs like remdesivir in patients under 65 years old. However, close monitoring of its safety is still necessary for elderly patients aged 65 years and above. Further studies are warranted to continuously assess the safety profile of molnupiravir as its usage increases, especially in high risk populations.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Dai, Zhicheng
    Zhang, Jiafeng
    Tao, Zhengbo
    Gao, Rui
    Zhao, Qinghua
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [2] Movement disorders associated with antiseizure medications: A real-world disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System
    Zhou, Jianxing
    Wei, Zipeng
    Chen, Shengyang
    Xie, Helin
    Huang, Wei
    Liu, Maobai
    Wu, Xuemei
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (11) : 3389 - 3400
  • [3] Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment
    Li, Yanping
    Zhang, Ni
    Jiang, Tingting
    Gan, Lanlan
    Su, Hui
    Wu, Yuanlin
    Yang, Xue
    Xiang, Guiyuan
    Ni, Rui
    Xu, Jing
    Li, Chen
    Liu, Yao
    [J]. PEDIATRIC NEUROLOGY, 2024, 158 : 71 - 78
  • [4] A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen
    Du, Yikuan
    Guo, Zhuoming
    Xu, Bijun
    Yang, Yujia
    Hu, Mianda
    Hu, Yanghui
    Yang, Yurong
    Zhang, Mengting
    Wang, Zhenjie
    Guo, Xiaochun
    Huang, Yixing
    Zhu, Jinfeng
    Zhang, Weichui
    Yang, Chun
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [5] A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
    Lin, Yu
    Zheng, Xinlei
    Chen, Yan
    Nian, Qichun
    Lin, Li
    Chen, Maohua
    [J]. HELIYON, 2024, 10 (06)
  • [6] A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib
    Peng, Ling
    Xiao, Kui
    Ottaviani, Silvia
    Stebbing, Justin
    Wang, Ying-Jie
    [J]. EXPERT OPINION ON DRUG SAFETY, 2020, 19 (11) : 1505 - 1511
  • [7] A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
    He, Yue
    Zhang, Rong
    Shen, Huarui
    Liu, Yingqi
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [8] Real world analysis of cardiac adverse events associated with clozapine: A pharmacovigilance analysis using food and drug administration adverse event reporting system
    Thotamgari, Sahith Reddy
    Bath, Anandbir S.
    Dhaliwal, Lovekirat
    Kommineni, Sai Karthik
    Aujla, Perminder
    Brar, Vijaywant
    [J]. GENERAL HOSPITAL PSYCHIATRY, 2022, 78 : 123 - 125
  • [9] Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system
    Chen, Jiao-Jiao
    Huo, Xue-Chen
    Wang, Shao-Xia
    Wang, Fei
    Zhao, Quan
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1351 - 1360
  • [10] Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system
    Jiao-Jiao Chen
    Xue-Chen Huo
    Shao-Xia Wang
    Fei Wang
    Quan Zhao
    [J]. International Journal of Clinical Pharmacy, 2022, 44 : 1351 - 1360